Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR)

Rheumatology International

Volumn 33, Issue 6, 2013, Pages 1475-1480

  Lee, Jung Hwa ^a   Choi, Sang Tae ^b   Kim, Jin Su ^b   Yoon, Bo Young ^c   Kwok, Seung Ki ^d   Kim, Hyun Sook ^e   Kim, Yun Sung ^e   Song, Jung Soo ^b   Lee, Sang Heon ^a   Kim, Hae Rim ^a  

^a Konkuk University School of Medicine   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Chosun University   (South Korea)

Author keywords

Polymyalgia rheumatica; Prognosis; Relapse; Steroid

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE;

AGED; ARTHRITIS; ARTICLE; CLINICAL FEATURE; CLINICAL STUDY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GIANT CELL ARTERITIS; HIP PAIN; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RHEUMATIC POLYMYALGIA; RISK FACTOR; SHOULDER PAIN; SYMPTOM; TREATMENT RESPONSE;

AGED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84878701257     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2580-4     Document Type: Article

References (24)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347:261-271
2. Gonzalez-Gay MA, Agudo M, Martinez-Dubois C, Pompei O, Blanco R (2010) Medical management of polymyalgia rheumatica. Expert Opin Pharmacother 11:1077-1087
3. Leeb BF, Bird HA (2004) A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 63:1279-1283
4. Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:26-35
5. Dasgupta B, Salvarani C, Schirmer M et al (2008) Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 35:270-277
6. Bird HA, Leeb BF, Montecucco CM et al (2005) A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis 64:626-629
7. Dasgupta B, Matteson EL, Maradit-Kremers H (2007) Management guidelines and outcome measures in polymyalgia rheumatica (PMR). Clin Exp Rheumatol 25:130-136
8. Dasgupta B, Borg FA, Hassan N et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49:186-190
9. Salvarani C, Cantini F, Macchioni P et al (1998) Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 41:1221-1226
10. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG (2000) The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 27:2179-2184
11. Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32:65-73
12. Smith CA, Fidler WJ, Pinals RS (1983) The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County Tennessee. Arthritis Rheum 26:1214-1219
13. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434-439
14. Wilke WS, Wysenbeek AJ, Krall PL, Segal AM (1985) Masked presentation of giant-cell arteritis. Cleve Clin Q 52:155-159
15. Myklebust G, Gran JT (1996) A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 35:1161-1168
16. Salvarani C, Cantini F, Niccoli L et al (2005) Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 53:33-38
17. Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 52:847-850
18. Hutchings A, Hollywood J, Lamping DL et al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57:803-809
19. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT (2010) Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 49:716-722
20. Ornetti P, Guillibert-Karras C, Garrot JF et al (2011) Study of professional practices among rheumatologists in Burgundy: initial corticotherapy in polymyalgia rheumatica. Clin Rheumatol 30:51-56
21. Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosch X (2009) Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 169:1839-1850
22. Cimmino MA, Parodi M, Caporali R, Montecucco C (2006) Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 1069:315-321
23. Cantini F, Salvarani C, Olivieri I et al (2000) Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 30:17-24
24. Caporali R, Cimmino MA, Ferraccioli G et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493-500